omega-n-methylarginine has been researched along with Kaposi Sarcoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kossenkov, A; Lieberman, PM; Ngalamika, O; Soldan, S; Su, C; Tso, FY; Vladimirova, O; West, JT; Wood, C | 1 |
| Barnett, JB; Soderberg, LS | 1 |
2 other study(ies) available for omega-n-methylarginine and Kaposi Sarcoma
| Article | Year |
|---|---|
Elevated iNOS and 3'-nitrotyrosine in Kaposi's Sarcoma tumors and mouse model.
Topics: Animals; Antigens, Viral; Herpesvirus 8, Human; Humans; Mice; omega-N-Methylarginine; Sarcoma, Kaposi; Tumor Microenvironment | 2023 |
Inhalation exposure to isobutyl nitrite inhibits macrophage tumoricidal activity and modulates inducible nitric oxide.
Topics: Administration, Inhalation; Animals; Arginine; Cell Adhesion; Cell Division; Cell Transformation, Neoplastic; Cells, Cultured; Cytotoxicity, Immunologic; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Interferon-gamma; Killer Cells, Natural; Lipopolysaccharides; Macrophages, Peritoneal; Mice; Mice, Inbred C57BL; Nitric Oxide; Nitrites; omega-N-Methylarginine; Sarcoma, Kaposi; Tumor Necrosis Factor-alpha; Vasodilator Agents | 1995 |